drugset / Trial / NCT03461458

Autologous, Culture-Expanded Mesenchymal Stromal Cells for Degenerative Disc Disease

NCT03461458

Phase 1 Terminated 1 enrolled Mayo Clinic
Non-randomizedSequentialOpen-labelTreatment

Summary

To determine the safety and feasibility of autologous, culture-expanded adipose-derived (AD) mesenchymal stromal cells (MSCs) in subjects with painful degenerative disc disease (DDD).

Timeline

Start
2018-10-17
Primary completion
2021-02-06
Completion
2021-02-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous Adipose-Derived Mesenchymal Stromal Cells Cell therapy 5e+06 cells Other
Subject Autologous Adipose-Derived Mesenchymal Stromal Cells Cell therapy 2e+07 cells Other